• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

5.350 -0.150 (-2.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,936,311
Open 5.400
Bid (Size) 5.350 (2,100)
Ask (Size) 5.500 (100)
Prev. Close 5.500
Today's Range 5.200 - 5.460
52wk Range 4.910 - 14.00
Shares Outstanding 95,568,307
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Roblox Corporation (NYSE: RBLX); Symbotic Inc. (NASDAQ: SYM); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your
Today 8:03 EDT
From Grabar Law Office
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
August 21, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire

Performance

YTD
-53.4%
-53.4%
1 Month
-9.9%
-9.9%
3 Month
-34.5%
-34.5%
6 Month
-41.9%
-41.9%
1 Year
-60.4%
-60.4%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
August 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript ↗
August 20, 2026
Via The Motley Fool
Topics Earnings
News headline image
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026
August 20, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
August 18, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026
August 18, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
August 18, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on
August 18, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
August 17, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
August 16, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
August 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf
August 14, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Q2 Earnings Call Highlights ↗
August 13, 2026
Via MarketBeat
Topics Earnings
News headline image
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026
August 13, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
August 13, 2026
Via Benzinga
Topics Earnings
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
August 13, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
August 13, 2026
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY
August 13, 2026
Via Newsfile
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
August 11, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
August 11, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
August 11, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
August 10, 2026
From DJS LAW GROUP
Via Business Wire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
August 08, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
August 07, 2026
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
The current price of ARS Pharmaceuticals, Inc. - Common Stock is 5.350
When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 08/24/26 04:00 PM ET
What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 511.29M
How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
ARS Pharmaceuticals, Inc. - Common Stock has 511M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap